← Back to Clinical Trials
Recruiting NCT06407427

NCT06407427 Evaluating the Efficacy of a Mobile Application in Postoperative Rehabilitation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06407427
Status Recruiting
Phase
Sponsor Yale University
Condition Spine Degeneration
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2025-07-21
Primary Completion 2026-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
App for in-bed conditioning exercisesUsual care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2025-07-21 with a primary completion date of 2026-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to evaluate the effectiveness of a mobile application in improving postoperative rehabilitation outcomes among patients undergoing orthopedic surgery.

Eligibility Criteria

Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * English reading/speaking * Are status post low-energy hip fracture, total knee/hip arthroplasty, or single to multilevel spinal fusion without paralysis * Must be able bodied enough to participate in a mobile app tool for physical therapy * Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration\] Exclusion Criteria: * Severe cognitive impairment: Not alert and oriented to person, place, time, and reason for being the hospital; and unable to follow 2 step commands * Severe physical impairment: * Neurologic paralysis * Polytraumas with restrictions incompatible with anti-gravity exercises * Knee immobilization, bed rest * Unstable medical conditions: * On ventilatory support * Utilizing high degrees of oxygen support (continuous BiPAP, high flow nasal cannula, nonrebreather mask, aerosol mask \>3L/min) * Hemodynamic instability requiring pressor medication support (can include those on pressors for elevated mean arterial pressure goals (MAPs)) * Neurologically instable with strokes, hemorrhages, increased intracranial pressures * Open wounds or surgical incisions * Tenuous closed wounds requiring immobilization or bending restrictions * Open wounds that are either packed/dressed or dressed with a wound vacuum * Surgical wounds that are draining fluid or purulence * Vulnerable populations * Incarcerated individuals * Patients without access to a mobile phone with iOS capability

Contact & Investigator

Central Contact

Rajiv S Vasudevan, M.D.

✉ Rajiv.vasudevan@yale.edu

📞 650-714-7908

Principal Investigator

Rajiv S Vasudevan, M.D.

PRINCIPAL INVESTIGATOR

Yale University

Frequently Asked Questions

Who can join the NCT06407427 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Spine Degeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06407427 currently recruiting?

Yes, NCT06407427 is actively recruiting participants. Contact the research team at Rajiv.vasudevan@yale.edu for enrollment information.

Where is the NCT06407427 trial being conducted?

This trial is being conducted at New Haven, United States.

Who is sponsoring the NCT06407427 clinical trial?

NCT06407427 is sponsored by Yale University. The principal investigator is Rajiv S Vasudevan, M.D. at Yale University. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology